Ant Group Launches AI-Powered Mobile App Zhixiaobao at 2024 INCLUSION·Conference on the Bund
5.9.2024 10:55:00 CEST | Business Wire | Press release
Other AI-powered products were also introduced to make AI more accessible for industries and consumers
At the 2024 INCLUSION · Conference on the Bund in Shanghai, Ant Group launched the Zhixiaobao mobile app, an AI life assistant that better connects users with all kinds of life services on the company’s digital life platform Alipay. The app is available for download from iOS and Android app stores.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904932587/en/
Ant Group unveiled AI life assistant app – Zhixiaobao, at the 2024 INCLUSION · Conference on the Bund. (Graphic: Business Wire)
As an AI-native application powered by Ant Group’s BaiLing foundation model, Zhixiaobao is designed to make everyday tasks easier through user-friendly interactions. Through typing or voice chat in Zhixiaobao, users can order meals, hail taxis, book tickets, and discover local dining and entertainment options, accessing third-party services in Alipay more easily.
The app also provides a number of built-in AI agents, each with specific domain knowledge that makes them an expert in their own fields. For example, the “English Language Tutor” agent can help users make a learning plan and provide tips for learning the language. The “Fitness Pro” agent can help users design workout routines and come up with personalized training advice.
"The evolution of AI extends beyond mere technological progress, it’s about applying these advancements to practical, user-focused solutions. Alipay is committed to harnessing AI’s potential to improve the user experience, ensuring that AI assistants like Zhixiaobao become valuable tools in everyday life for all," said Cyril Han, President of Ant Group.
To use Zhixiaobao’s services, users can either download the dedicated mobile app, or simply pull down the home page of the Alipay app.
In addition to Zhixiaobao, Ant Group also introduced other AI-powered products and solutions at the INCLUSION Conference.
- An AI Agent Development Platform: A comprehensive, one-stop platform enabling merchants to create customized AI service agents which can be deployed in just one minute, without the need for coding. These agents can be effortlessly integrated into the Alipay mini-programs operated by merchants, the Alipay app, and the Zhixiaobao app.
- AI Healthcare Manager: An AI-powered platform that connects users to over 30 health services, including doctor recommendations, medical test result interpretation, in-hospital navigation, and personalized medical advice. The AI Healthcare Manager is supported by over 20 service providers, including Renji Hospital in Shanghai.
- Ant Bridge: An open platform that leverages advanced technologies including AI models and financial intelligence, to assist insurance companies in providing personalized responses to customer inquiries in real-time. The platform is designed to support insurers to enhance their service quality while boosting operational efficiency.
Ant Group unveiled its BaiLing foundation model in 2023. Over the past two years, Ant Group has accelerated the application of AI technologies in the Alipay app, serving hundreds of millions of users across various life service use cases, including travel, healthcare, and financial management.
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904932587/en/
Contacts
Media Inquiries
Media Inquiries
Vick Li Wei
vick.lw@antgroup.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom